<DOC>
	<DOCNO>NCT00952991</DOCNO>
	<brief_summary>Administration incretin hormone , Glucagon-Like-Peptide-1 ( GLP-1 ) , show enhance insulin secretion suppress glucagon secretion response meal ingestion . In addition , GLP-1 also delay gastric empty show enhance gastric accommodation . These characteristic make GLP-1 ideal therapy type 2 diabetes ( T2D ) . However , rapid breakdown dipeptidylpeptidase IV ( DPP IV ) , GLP-1 administer continuous intravenous infusion . This would drawback clinical usage . LAF237 synthetic inhibitor DPP IV show raise GLP-1 level potentiate meal-induced insulin secretion glucagon suppression . However , effect LAF237 gastric empty satiety present unknown . The investigator propose study effect LAF237 gastric emptying , gastric volume satiety patient T2D addition examine direct indirect ( mediate via insulin glucagon ) compound postprandial glucose metabolism .</brief_summary>
	<brief_title>The Effects LAF237 Gastric Function Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Type 2 diabetes without microvascular macrovascular complication treat diet 2 oral agent</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>